Polygenic risk score in comparison with C-reactive protein for predicting incident coronary heart disease.

[1]  A. Uitterlinden,et al.  Coronary Artery Calcium Score and Polygenic Risk Score for the Prediction of Coronary Heart Disease Events. , 2023, JAMA.

[2]  E. Ashley,et al.  Polygenic risk scores for the prediction of cardiometabolic disease. , 2022, European heart journal.

[3]  G. Schuler,et al.  Biomarkers for Non-Invasive Stratification of Coronary Artery Disease and Prognostic Impact on Long-Term Survival in Patients with Stable Coronary Heart Disease , 2022, Nutrients.

[4]  M. Pencina,et al.  Predictive Utility of a Validated Polygenic Risk Score for Long-Term Risk of Coronary Heart Disease in Young and Middle-Aged Adults , 2022, Circulation.

[5]  E. Ashley,et al.  Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association , 2022, Circulation.

[6]  Matthew S. Lebo,et al.  Development of a clinical polygenic risk score assay and reporting workflow , 2022, Nature Medicine.

[7]  E. Boerwinkle,et al.  American Heart Association’s Life’s Simple 7: Lifestyle Recommendations, Polygenic Risk, and Lifetime Risk of Coronary Heart Disease , 2022, Circulation.

[8]  Jin Liu,et al.  Independent and joint effects of high-sensitivity c-reactive protein and hypoalbuminemia on long-term all-cause mortality among coronary artery disease: a prospective and multicenter cohort study , 2021, BMC Cardiovascular Disorders.

[9]  P. Natarajan,et al.  Clinical utility of polygenic risk scores for coronary artery disease , 2021, Nature Reviews Cardiology.

[10]  Thomas J. Wang,et al.  Polygenic Risk Score to Identify Subclinical Coronary Heart Disease Risk in Young Adults , 2021, Circulation. Genomic and precision medicine.

[11]  P. Harst,et al.  Polygenic risk score and coronary artery disease: A meta-analysis of 979,286 participant data. , 2021, Atherosclerosis.

[12]  E. McVeigh,et al.  Targeted Coronary Artery Calcium Screening in High-Risk Younger Individuals Using Consumer Genetic Screening Results. , 2021, JACC. Cardiovascular imaging.

[13]  A. Khera,et al.  Genome-Wide Polygenic Score, Clinical Risk Factors, and Long-Term Trajectories of Coronary Artery Disease , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[14]  C. Kooperberg,et al.  Improving reporting standards for polygenic scores in risk prediction studies , 2020, Nature.

[15]  C. Robinson-Cohen,et al.  Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease. , 2020, JAMA.

[16]  P. Elliott,et al.  Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease. , 2020, JAMA.

[17]  G. Abecasis,et al.  Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial , 2019, Circulation.

[18]  P. Ellinor,et al.  Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score , 2019, Circulation.

[19]  A. Dale,et al.  Using a genetic risk score to calculate the optimal age for an individual to undergo coronary artery calcium screening. , 2019, Journal of cardiovascular computed tomography.

[20]  J. Danesh,et al.  Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults , 2018, Journal of the American College of Cardiology.

[21]  Mary E. Haas,et al.  Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.

[22]  E. Ashley,et al.  Cardiovascular disease: The rise of the genetic risk score , 2018, PLoS medicine.

[23]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[24]  A. Khera,et al.  Multimodality Strategy for Cardiovascular Risk Assessment: Performance in 2 Population-Based Cohorts , 2017, Circulation.

[25]  Dermot F. Reilly,et al.  Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting , 2017, Circulation.

[26]  William K. Thompson,et al.  Defining a Contemporary Ischemic Heart Disease Genetic Risk Profile Using Historical Data , 2016, Circulation. Cardiovascular genetics.

[27]  E. Boerwinkle,et al.  Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. , 2016, The New England journal of medicine.

[28]  John-Michael Sauer,et al.  Net Reclassification Index and Integrated Discrimination Index Are Not Appropriate for Testing Whether a Biomarker Improves Predictive Performance. , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[29]  H. Staines,et al.  Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome , 2016, European journal of preventive cardiology.

[30]  Paul M Ridker,et al.  The Present and FutureReview Topic of the WeekA Test in Context: High-Sensitivity C-Reactive Protein , 2016 .

[31]  E. Tai,et al.  C-reactive protein and serum creatinine, but not haemoglobin A1c, are independent predictors of coronary heart disease risk in non-diabetic Chinese , 2016, European journal of preventive cardiology.

[32]  Cheng-gang Zhu,et al.  C-reactive protein as a predictor for poor collateral circulation in patients with chronic stable coronary heart disease , 2016, Annals of medicine.

[33]  P. Visscher,et al.  Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores , 2015, bioRxiv.

[34]  J. Jeppesen,et al.  Adipocytokines, C-Reactive Protein, and Cardiovascular Disease: A Population-Based Prospective Study , 2015, PloS one.

[35]  M. Pencina,et al.  How to interpret a small increase in AUC with an additional risk prediction marker: decision analysis comes through , 2014, Statistics in medicine.

[36]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[37]  Fernando Rivadeneira,et al.  Improving accuracy of rare variant imputation with a two-step imputation approach , 2014, European Journal of Human Genetics.

[38]  David Levine,et al.  A high-performance computing toolset for relatedness and principal component analysis of SNP data , 2012, Bioinform..

[39]  Kenny Q. Ye,et al.  An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.

[40]  Lloyd E Chambless,et al.  Several methods to assess improvement in risk prediction models: Extension to survival analysis , 2011, Statistics in medicine.

[41]  Rongwei Fu,et al.  C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force , 2009, Annals of Internal Medicine.

[42]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[43]  M. Pencina,et al.  C-Reactive Protein and Reclassification of Cardiovascular Risk in the Framingham Heart Study , 2008, Circulation. Cardiovascular quality and outcomes.

[44]  Marcus D. Ruopp,et al.  Youden Index and Optimal Cut‐Point Estimated from Observations Affected by a Lower Limit of Detection , 2008, Biometrical journal. Biometrische Zeitschrift.

[45]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[46]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[47]  D. Levy,et al.  C-Reactive Protein Is Associated With Subclinical Epicardial Coronary Calcification in Men and Women: The Framingham Heart Study , 2002, Circulation.

[48]  A. Folsom,et al.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. , 1989, American journal of epidemiology.

[49]  J. Albers,et al.  Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. , 1982, Clinical chemistry.

[50]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.

[51]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.

[52]  T. Dawber,et al.  Epidemiological approaches to heart disease: the Framingham Study. , 1951, American journal of public health and the nation's health.

[53]  OUP accepted manuscript , 2022, European Heart Journal.

[54]  Kathleen F. Kerr,et al.  Net reclassification indices for evaluating risk prediction instruments: a critical review. , 2014, Epidemiology.

[55]  B. Astor,et al.  Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study). , 2012, The American journal of cardiology.